Trident Texofab Ltd

On 26-Dec, Trident Texofab Ltd experienced a notable decline in its share price, falling by 2.71% to close at ₹249.80. This drop reflects a continuation of recent downward momentum despite the company’s strong long-term performance relative to the broader market.

As of December 4, 2025, Trident Texofab is considered very expensive with a PE ratio of 171.99 and significantly higher valuation metrics compared to its peers, indicating that its impressive stock performance may not be justified by its fundamentals.

As of December 3, 2025, the trend is mildly bullish, supported by daily moving averages and Bollinger Bands, though caution is advised due to a mildly bearish weekly MACD and bearish monthly RSI.

Trident Texofab has shown steady growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, with profits also rising significantly. However, cash flow from operating activities turned negative in Mar'25, indicating challenges in cash management despite overall financial growth.

As of November 18, 2025, Trident Texofab is considered very expensive and overvalued, with a PE ratio of 174.34 and other high valuation metrics, indicating that investors may be overpaying despite the stock's recent strong performance.

As of November 17, 2025, Trident Texofab is considered overvalued with a valuation grade of expensive, reflected by its high PE ratio of 170.80 and other elevated metrics compared to industry peers.

As of 17-Nov, Trident Texofab Ltd's stock price is Rs 337.50, up 2.9% today and showing strong long-term growth with a 100.65% year-to-date increase. However, a significant drop in delivery volume raises concerns about ongoing investor interest despite recent gains.

Trident Texofab has shown steady growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, despite fluctuations in costs and a decline in operating profit margins. Profit after tax rose to 2.51 Cr in Mar'25, but cash flow from operations turned negative at -13.00 Cr.

Trident Texofab has shown steady growth in net sales and profits from Mar'21 to Mar'25, with net sales increasing from 49.93 Cr to 122.06 Cr, although it faced fluctuations in costs and a negative cash flow of -13.00 Cr in Mar'25. Total liabilities and assets both rose to 100.58 Cr during this period, indicating overall growth despite challenges.

Trident Texofab has shown steady growth in net sales, reaching 122.06 Cr in Mar'25, with profits before and after tax increasing to 2.58 Cr and 2.51 Cr, respectively. Despite negative cash flow from operating activities, the company improved its financial health with reduced debt and increased equity capital and reserves.

Trident Texofab has shown consistent growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, with total assets rising to 100.58 Cr and earnings per share improving to 1.85. The company also reduced its total debt, indicating enhanced financial health and profitability.